<DOC>
	<DOCNO>NCT01349348</DOCNO>
	<brief_summary>To evaluate efficacy safety Tolvaptan 7.5mg 15mg treatment patient cirrhosis ascites fail response adequately treatment common diuretic .</brief_summary>
	<brief_title>Phase III Study Tolvaptan Tablet Treat Cirrhosis Ascites</brief_title>
	<detailed_description>For symptom fluid retention due liver disease ( ascites and/or low extremity edema , i.e . hepatic edema ) , treatment generally start bed rest low-salt diet . Aldosterone antagonists loop diuretic commonly use diuretic treatment fluid retention due liver disease . In aldosterone antagonist ' therapy , nevertheless , hyperkalemia frequently report , slow onset action dose escalation need also impair effect . If aldosterone antagonist ' therapy ineffective , loop diuretic strong diuretic usually add . However , Dose escalation loop diuretic also boost occurrence hyponatremia hypokalemia , combination two drug provide fast onset effectiveness less adverse event . While , diuretic cause sodium lose difficult prevent treat , hyponatremia easy occur . The combination aldosterone antagonists K-sparing diuretic reduces occurrence hypokalemia little effect prevention treatment hyponatremia . In addition , still patient resistent loop diuretic intolerant effective diuretic dosage due adverse event . Tolvaptan increase excretion electrolyte-free water ( aquaretic ) without change electrolyte excretion inhibit water reabsorption collect duct kidney . It demonstrate Tolvaptan increase urine volume without impair renal function .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients diagnose liver cirrhosis clinically pathologically ; 2 . Patients ascites confirmed TypeB ultrasound scan receive combination therapy oral loop diuretic aldosterone antagonist least 4 day fix usage dosage 3 . Inpatients patient hospitalize study Day 3 ( Screening ) Day 8 ( day efficacy evaluation ) ; 4 . Patients body weight change within ±1.0 kg 2 day prior initiation treatment ( Day 2 Day 1 ) 5 . Age : 18 75 year , inclusive ( time inform consent obtain ) ; 6 . Genders : men woman ; 7 . Patients sign informed consent form . Exclusion criterion : 1 . Patients follow disease , complication symptom : Hepatic encephalopathy ( hepatic coma grade II higher1） ) ; Malignant ascites ( patient tumor cell detect ascites malignant ascites highly suspect ) ; Uncontrolled spontaneous bacterial peritonitis ; Patients likely experience alimentary tract hemorrhage study ; Heart failure ( NYHA2） grade III IV ) ; Anuresis ( daily urine volume le 100mL ) ; Dysuria due urinary tract stricture , urinary calculus , tumor urinary tract cause . 2 . Patients history : Alimentary tract hemorrhage within 10 day prior screen ; Cerebral accident suffer within 30 day prior screen ; Past history hypersensitivity idiosyncratic reaction benzazepine derivative ( Benazepril ) . 3 . Patients systolic pressure 90mmHg screening ; 4 . Patients follow abnormal laboratory parameter screen : Serum creatinine &gt; 1.5x upper limit normal range ; Serum Na+ &gt; 145mmol/L ( high upper limit normal range ) ; Serum K+ &gt; 5.5mmol/L ; 5 . Patients Childpugh score3） &gt; 12 ; 6 . Patients unable take medicine orally ; 7 . Female patient pregnant , lactating , childbearing age without use acceptable contraceptive mean ; 8 . Patients receive blood product include albumin within 4 day prior initiation treatment 9 . Patients participate clinical trial tolvaptan within one month prior screen ; 10 . Patients participate Tolvaptan trial take Tolvaptan previously ; 11 . Patients otherwise judged investigator , inappropriate inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Tolvaptan treatment ascites hepatic cirrhosis</keyword>
</DOC>